Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Galecto Inc (NQ: GLTO ) 6.920 -0.240 (-3.35%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 10, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Galecto Inc Galecto Inc. (NASDAQ: GLTO) Leading the Way in Tuesday Trading Based on Percentage Gain July 25, 2023 Via Investor Brand Network Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022 March 09, 2023 From Galecto, Inc. Via GlobeNewswire Galecto to Participate in Oppenheimer’s 33rd Annual Healthcare Conference March 02, 2023 From Galecto, Inc. Via GlobeNewswire Galecto to Participate in SVB Securities Global Biopharma Conference February 01, 2023 From Galecto, Inc. Via GlobeNewswire Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting December 07, 2022 From Galecto, Inc. Via GlobeNewswire Galecto Reports Third Quarter Operating and Financial Results November 08, 2022 From Galecto, Inc. Via GlobeNewswire Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients November 08, 2022 From Galecto, Inc. Via GlobeNewswire Galecto to Participate in Jefferies London Healthcare Conference November 03, 2022 From Galecto, Inc. Via GlobeNewswire Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD’s The Liver Meeting® 2022 October 31, 2022 From Galecto, Inc. Via GlobeNewswire Galecto’s Galectin-3 Inhibitor GB1211 to be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute October 19, 2022 Phase 2 investigator-initiated trial to be supported by an NCI grant to Providence Cancer Institute in Portland, Oregon to study a combination of pembrolizumab and a galectin-3 inhibitor From Galecto, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
